估值35亿，成立10年的AI生物制造冲刺IPO！获高瓴、礼来青睐，单品全球第一！

Core Viewpoint - The company, a leader in AI-driven biomanufacturing, has achieved a valuation of 3.5 billion RMB and an annual production capacity exceeding 10,000 tons within ten years since its establishment in 2015 [1][3]. Company Overview - Founded in 2015 and headquartered in Suzhou, the company has established production bases in Hunan and Anhui, making it one of the few synthetic biology firms with a full chain capability from R&D to commercialization [3]. - The founder, Dr. Xie Xinkai, is a notable figure in synthetic biology, having studied under pioneers in the field and is credited with the first synthesis of simvastatin [3]. Financial Performance - The company reported a D-round post-investment valuation of 3.484 billion RMB, with its revenue structure primarily consisting of pharmaceutical intermediates, human nutrition, and animal nutrition [3]. - Revenue is projected to grow from 297.76 million RMB in 2023 to 344.59 million RMB in 2024, representing a 15.7% increase, and further to 379.99 million RMB in 2025, marking a 52.9% growth [7]. - The company has not yet achieved profitability, but losses are steadily narrowing, with net losses recorded at 146.55 million RMB for 2023 and 253.92 million RMB for 2024 [8]. Market Position - The company holds a significant market share in key products, ranking second globally in florfenicol (24.5%) and first in D-ethyl (44.5%), with its NMN product also holding a 11.4% market share [4]. - The primary product, florfenicol, is a veterinary antibiotic with a market size exceeding 3 billion RMB, while D-ethyl is a crucial intermediate for this drug [5]. Technological Advancements - The company has developed an enzyme-based synthesis process that addresses the inefficiencies of traditional multi-step chemical synthesis, leading to a more environmentally friendly and cost-effective production method [6]. - It has built a robust enzyme library containing over 10,000 enzymes and plans to integrate AI tools throughout its engineering workflow to enhance efficiency and automation [9][12]. Investment and Support - The company has a strong backing from prominent investors, including Yuexiu Capital, CICC Capital, and Hillhouse Capital, who recognize its technological advancements in biocatalysis [12].